Alissa Visram

The importance of syngeneic mouse models for CART studies: cell.com/molecular-ther…

Great slide on diagnostic algorithm for suspected AL #Amyloidosis #ISA2022

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database with @ArleighMccurdy @VisramAlissa @vhugo8762 @JStakiw @ResearchMyeloma @AnnetteHay1 onlinelibrary.wiley.com/doi/10.1002/jh…

COVID amplified disparities in healthcare access and availability in the US, leading to disparities in outcomes by race and ethnicity.

@NoopurRajeMD @HiraSMian Entirely agree! Hira has been such an incredible advocate for me, I'm very grateful!

This is what mentorship is all about @HiraSMian❣️

@ninashah33 @HiraSMian Thank you!

Important analysis on impact of marginalization on treatment timing and survival in a universal medical system. So many complicated factors but steps to access (not just access itself) probably among the most important. Congrats to @VisramAlissa @HiraSMian #mmsm #IMS2022

Important discussion by Dr. Alissa Visram at #IMS2022 on the impact of marginalization on treatment receipt and OS in NDMM in a population-based Ontario, Canada cohort #mmsm

Canadians on the stage! Congrats! @ArleighMccurdy @HiraSMian @VisramAlissa #imw22

Fantastic session on induction for #mmsm #IMS2022: transplant, maintenance, frailty impacting treatment choice, and access to care for marginalized populations.. special shout out to Dr. Visram for a great presentation.

@NoopurRajeMD Thank you! :)

@HiraSMian @HSeowPhD @gpond1 @machealthsci @MyelomaCanada Thank you!!

Dr Visram so so proud of her for presenting our work on marginalization in MM in Ontario on a massive stage at #IMS2022 @VisramAlissa @HSeowPhD @gpond1 @machealthsci @MyelomaCanada

Congratulations @VisramAlissa !

#Myeloma Paper of the Day: Monoclonal proteinuria may help to predict progression risk in asymptomatic multiple #myeloma patients with a free light chain ratio ≥100: pubmed.ncbi.nlm.nih.gov/35190659/.

Amazing that these two have been working so hard to keep people well and the hospital running from the very start of the pandemic. Thanks @sam_halman and @isa_desj; you are absolute @OttawaHospital superstars! ottawa.ctvnews.ca/the-women-led-…

#Myeloma Paper of the Day: Family history of plasma cell disorders is associated with an improved overall survival in #MGUS, multiple #myeloma, and systemic AL #amyloidosis: pubmed.ncbi.nlm.nih.gov/34764424/.

#Myeloma Paper of the Day: Study assessing prognostic utility of serial smoldering #myeloma risk stratification scores finds patients evolving to high-risk category progress more often and may benefit from early intervention approaches: pubmed.ncbi.nlm.nih.gov/34836942/.

Importance of serial testing in myeloma precursor disease from prospective NCI PLCO study: jamanetwork.com/journals/jamao… Results confirmed and expanded by large independent Mayo Clinic study. #mmsm ⁦@IMFmyeloma⁩ ⁦@theMMRF⁩ ⁦@sykristinsson⁩ #article-info" target="_blank" rel="nofollow noopener">nature.com/articles/s4140…

Important study in smoldering #myeloma published by Mayo in @BloodCancerJnl Risk is dynamic and should be reassessed yearly. Authors acknowledged the limitation of marrow assessment only at baseline Solution➡️CTCs. That is our aim in the iMMunocell project #article-info" target="_blank" rel="nofollow noopener">nature.com/articles/s4140…

True success is the freedom to stop caring about how anyone else defines success.